Vertex Pharmaceuticals (VRTX)

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Discover how Vertex Pharmaceuticals (VRTX) combines strong fundamentals, like high profitability and no debt, with a bullish technical breakout pattern for potential growth.

These two have been neglected by Wall Street too much.

Vertex appears to be by far the better buy right now.

There's no guarantee that any stock will deliver positive returns. But the odds look good for these three.

Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers.

These companies have a habit of beating the market, and they are far from having peaked.

These companies' market-beating fuel hasn't run out yet.

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

Vertex Pharmaceuticals (VRTX) offers strong growth, solid earnings, and a robust financial position, all at a reasonable price compared to biotech peers.

Here are two smart ways to prepare for the next market downturn.

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Vertex isn't your run-of-the-mill biotech stock.

Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This might have investors contemplating their next move.

Tariffs aren't likely to weigh on growth at these companies.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.

The market is sleeping on these stocks, but you don't have to.

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for sustainability. This dynamic landscape is giving rise to several high-growth sectors that are not only reshaping industries but also presenting unprecedented investment opportunities.

Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX).